Genetic Markers Could Affect Antidepressant Treatment
Adults taking venlafaxine may find that genetic variations influence how their body breaks down the medication.
Updated on Oct. 15, 2026 in Mental Health

Live Poll
Should genetic testing be standard practice before starting new medications to prevent ineffective treatment?
A 2026 study linked specific genetic markers to how the body metabolizes the antidepressant venlafaxine. The findings suggest that individuals with slower metabolism of the drug may be twice as likely to switch medications due to side effects or lack of efficacy.
Why it matters
Understanding how genetic variations influence drug breakdown could eventually help clinicians tailor antidepressant prescriptions. Identifying these metabolic differences may reduce the trial-and-error process currently involved in finding an effective treatment.
This retrospective study analyzed data from 5,400 Norwegian patients and 3,600 United Kingdom patients to track medication usage. While a link exists between metabolism speed and switching rates, it remains unknown if implementing pre-treatment testing improves clinical results.
The players
The Centre for Psychopharmacology
An organization that conducts approximately 10,000 metabolism tests annually.
The Lancet Psychiatry
A medical journal that published the retrospective study in 2026.
The details
The liver relies on specific enzymes to break down venlafaxine into a usable form. Genetic differences in enzyme activity cause these metabolic rates to vary between individuals. Because slow metabolizers may experience the drug differently, researchers suggest that lower doses might be necessary for this group to avoid side effects or treatment discontinuation.
Timeline
2005-2025: Data collection period for the Norwegian patient cohort.
2025: Period during which 39,000 Norwegians used venlafaxine.
2026: Publication of the study results in The Lancet Psychiatry.
Health Landscape
The use of genetic testing for drug metabolism is an evolving area of pharmacogenomics. This study provides new evidence that expands the clinical utility of the metabolic testing currently conducted at the Centre for Psychopharmacology.
If you are taking venlafaxine, consider discussing your treatment experience with your doctor, especially if you have faced side effects or a lack of therapeutic effect. Genetic test results remain constant throughout your life, but clinical application remains a topic to review with a physician.
The takeaway
Genetic differences can significantly influence how your body processes antidepressants. Always discuss persistent side effects or concerns about medication efficacy with your physician, who can determine if further testing or a dosage adjustment is appropriate for your specific needs.
Further reading
For more information on managing medication, visit Mental Health.
Source note: This article includes information reported by Sciencenorway.
Live Poll
Should genetic testing be standard practice before starting new medications to prevent ineffective treatment?


